503959583 08/15/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4006238

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ALBERTO ORTEGA MUÑOZ	07/08/2016
MATTHEW COLIN THOR FYFE	07/11/2016
MARC MARTINELL PEDEMONTE	07/11/2016
MARIA DE LOS ANGELES ESTIARTE MARTINEZ	07/11/2016
NURIA VALLS VIDAL	07/11/2016
GUIDO KURZ	07/11/2016
JULIO CESAR CASTRO PALOMINO LARIA	07/11/2016

RECEIVING PARTY DATA

Name:	ORYZON GENOMICS S.A.
Street Address:	C/SANT FERRAN 74
City:	CORNELLÀ DE LLOBREGAT (BARCELONA)
State/Country:	SPAIN
Postal Code:	08940

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14352711

CORRESPONDENCE DATA

Fax Number: (202)408-4400

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-408-4000

Email: pam.gebhardtsbauer@finnegan.com

Correspondent Name: FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

Address Line 1: 901 NEW YORK AVE., NW Address Line 4: WASHINGTON, D.C. 20001

ATTORNEY DOCKET NUMBER:	12064.0019-00000
NAME OF SUBMITTER:	PAMELA A. GEBHARDTSBAUER
SIGNATURE:	/Pamela A. Gebhardtsbauer/
DATE SIGNED:	08/15/2016

PATENT 503959583 REEL: 039430 FRAME: 0763

Total Attachments: 14 source=SignedAssignments#page1.tif source=SignedAssignments#page2.tif source=SignedAssignments#page3.tif source=SignedAssignments#page4.tif source=SignedAssignments#page5.tif source=SignedAssignments#page6.tif source=SignedAssignments#page7.tif source=SignedAssignments#page8.tif source=SignedAssignments#page9.tif source=SignedAssignments#page10.tif source=SignedAssignments#page11.tif source=SignedAssignments#page12.tif source=SignedAssignments#page12.tif source=SignedAssignments#page13.tif source=SignedAssignments#page14.tif

PATENT REEL: 039430 FRAME: 0764

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and:

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, IWE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz

Address [Address] C/O DAYFON GENDMICS, S.A.

CALLE SANT FERROW, 74, 1894O CORNELLA DE LLANGEDAT, SPRIN

By:

Date: JULY No Dol6

Name: Address:	Matthew Colin Thor Fyfe [Address]
By: Date:	
Name: Address:	Marc Martinell Pedemonte [Address]
By: Date:	
Name: Address:	Maria de los Ángeles Estiarte Martínez [Address]
By: Date:	
Name: Address:	Nuria Valls Vidal [Address]
By: Date:	
Name: Address:	Guido Kurz [Address]
By: Date:	
Name: Address:	Julio Cesar Castro Palomino Laria [Address]
By: Date:	
Assignee	
Signature	
Printed N	1
Corporate	
Date:	24-247-2016

Page 2 of 2

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name:	Alberto Ortega Muñoz	
Address:	[Address]	
.	<u> </u>	
By:		
Date:		

Name:	Matthew Colin Thor Fyfe		
Address:	[Address] CUIPTING NONTON		
	UNITED KINGDOM	M. Ho.	Ĭ
Ву:	Mattle Vile	1 1000000	
Date:	11 JULY 2016 U		
Name:	Marc Martinell Pedemonte		
Address	[Address]		
	<u> </u>		
Ву:			
Date:			
	المنافرة والمستراف الأراب والمسترافة المتافرة المتافرة المتافرة المتافرة المتافرة المتافرة المتافرة المتافرة ا		
Name:	Maria de los Ángeles Estiarte Martinez		
Address:	[Address]		
D			
By:			
Date:			
Name:	Nuria Valls Vidal		
	[Address]		
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
By:			
Date:			
Name:	Guido Kurz		
Address:	[Address]		
By:	N		
Date:			
Name:	Iulia Canas Cantra Dalamina Laria		
	Julio Cesar Castro Palomino Laria [Address]		
Addiess.	Mudiessi		
By:			
Date:			
Date.			
	/ //		
Assigne	e Name: Oryzon Gendmics S.A.	<u>.</u>	
•		Ž	
Signature	:		
		. wi	
Printed N	lame: <u>CAAUDI BUEIA ACOC</u>		
			
Corporate	e Title: \		
Date:	10-,1047-2016		
wate.	\		
	The state of the s		
	(\$) · 3		

Page 2 of 2

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Address:	Alberto Ortega Muñoz [Address]
By Date	

Name: Address:	Matthew Colin Thor Fyfe [Address]
By: Date:	
Name: Address: By:	Marc Martinell Pedemonte [Address] % As As &
Date:	DV-5-117h 2016
Name: Address:	María de los Ángeles Estiarte Martínez [Address]
By: Date:	
Name: Address:	Nuria Valls Vidal [Address]
By: Date:	
Name: Address:	Guido Kurz [Address]
By: Date:	
Name: Address:	Julio Cesar Castro Palomino Laria [Address]
By: Date:	
Assigne	e Name: Oryzon Genomics S.A.
Signature	·
Printed N	lame: / <u>CAPUSO BUSIA ARWU</u>
Corporat	e Title
Date:	29/242-2016
Page 2 o	f 2

Page 2 of 2

PATENT REEL: 039430 FRAME: 0770

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, IWE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, IWE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF. I/We have hereunto set our hands.

Name:	Alberto Ortega Muñoz	
Address:	[Address]	
Bv:		
Date:		
	200000000000000000000000000000000000000	

Name: Address:	Matthew Colin Thor Fyfe [Address]	
By: Date:		
Name: Address:	Marc Martinell Pedemonte [Address]	
By: Date:		
Name: Address:	Maria de los Ángeles Estiarte Martinez [Address] SEAN FRANCISCO, CA	
By: Date:	11 201 501	
Name: Address:	Nuria Valls Vidal [Address]	
By: Date:		
Name: Address:	Guido Kurz [Address]	
By: Date:		
Name: Address:	Julio Cesar Castro Palomino Laria [Address]	
By: Date:		
Assigne	/ / Mach)
Signature		
Printed N	ame: CAILLOC BURAL ARJOL	
Corporate	Title: C.E.O.	
Date:	- 32- MA-1418	

Page 2 of 2

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/568,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and:

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Liobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world:

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Address:	Alberto Ortega Muñoz [Address]
By: Date:	<u> </u>
	88

By: Date: Name: Marc Martinell Pedemonte Address: [Address]	
By: Date:	
Name: Maria de los Ángeles Estiarte Martinez Address: [Address]	
By: Date:	
Name: Nuria Valls Vidal Address: [Address] <u>C / V () 0 15 1° , 0 80 16</u> Exactions SPA ()	
By: Date: 1.00 C1	
Name: Guido Kurz Address: [Address]	
By: Date:	
Name: Julio Cesar Castro Palomino Laria Address: [Address]	
By: Date:	
Assignee Name: Oryzon Genomics S.A.	
Signature:) }
Printed Name: CARUS &UESA ANDOL	×
Corporate Title <u>CE-9</u>	
Date: 23-304-2046	

Page 2 of 2

PATENT REEL: 039430 FRAME: 0774

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world:

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name:	Alberto Ortega Muñoz	
Address:	[Address]	
By:	1	
Date:	· · · · · · · · · · · · · · · · · · ·	

Name:	Matthew Colin Thor Fyfe
Address:	[Address]
By: Date:	
Name: Address:	Marc Martinell Pedemonte [Address]
By: Date:	
Name: Address:	Maria de los Ángeles Estiante Martínez [Address]
By: Date:	
Name: Address:	Nuria Valls Vidal [Address]
By: Date:	
Name: Address;	Guido Kurz [Address] LLUIS DONEVECH JHOUTHUER 6
By: Date:	<u>0850 ESPLAGUES DE U</u> / UNITO
Name: Address	Julio Cesar Castro Palomino Laria [Address]
By: Date:	
Assignee	Name: Oryzon Genomics S.A.
Signature	
Printed N	ame: / <u>chalos buesa anos l</u>
Corporate	Title:
Date:	304 JULY-2016

Page 2 of 2

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and:

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world:

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Address:	Alberto Ortega Muñoz
	{ADG/ESS}
By: Date:	**************************************

Name: Address:	Matthew Colin Thor Fyfe [Address]
By: Date:	
Name: Address:	Marc Martinell Pedemonte [Address]
By: Date:	
Name: Address:	María de los Ángeles Estiarte Martínez [Address]
By: Date:	
Name: Address:	Nuria Valls Vidal [Address]
By: Date:	
Name: Address:	Guido Kurz [Address]
By: Date:	
Name: Address: By:	Julio Cesar Castro Palomino Laria [Address] ぞんめらご 仏の体 32 ○8307 ガムナムを ころしい
Date:	
Assigne	e Name: Oryzon Genomics S.A.
Signature	
Printed N	lame: CANOS BUESS ANDOC
Corporati	e Title <u>E. C/</u>
Date:	1
Page 2 o	f 2

PATENT REEL: 039430 FRAME: 0778

RECORDED: 08/15/2016